HIT > Therapy > MedicamentsV≡
[SIGHI]
Swiss Interest Group
Histamine Intolerance (SIGHI)
    Register
  • Login
Information about histamine related disorders (histaminosis),
for persons concerned and healthcare professionals
     Register
  • Login
[SIGHI]Swiss Interest Group
Histamine Intolerance (SIGHI)
Information about histamine related disorders (histaminosis),
for persons concerned and healthcare professionals
  • Introduction
  • News
  • Histaminosis
  • Symptoms
  • Diagnosis
  • Therapy
  • Self-help groups
  • Discussion forums
  • Frequently asked questions
  • Downloads
  • Links
  • Contact
  • Dietary change
  • Histamine potential
  • Cooking advice
  • Cooking recipes
  • Histamine app
  • Medicaments
  • Way of life
  • Purchasing tips
  • ⌕  Search
  • DE
  • EN
  • FR
  • Dietary change
  • Histamine potential
  • Cooking advice
  • Cooking recipes
  • Histamine app
  • Medicaments
  • Way of life
  • Purchasing tips


 
 

Translations may contain older or less detailed information than the original German page!

Medicaments

Symbolic picture: pills


Page overview:

  • Medication
    • Antihistamines
    • Diamine oxidase (DAO)
    • Mast cell stabilizers
    • Food supplements
  • Incompatible medicaments
    • Histamine liberators
    • Diamine oxidase inhibitors (DAO-blockers)
    • List of incompatible active substances in medicaments

Medication

The medication of histamine-related diseases like mast cell activity syndrome (MCAS), mastocytosis or histamine intolerance is described in detail in our SIGHI Medication Manual:

The SIGHI Medication Manual: pharmaceutical treatment of MCAD / Histaminosis

[COVER]

The SIGHI Medication Manual describes in detail and well-struc­tured on more than 120 pages the dif­fer­ent pos­sibil­ities of medical treatment for systemic mast cell activation diseases, histamine intol­er­ance or hist­aminosis and shows the advan­tages of numerous active substan­ces as well as their dis­advan­tages. In addition to phar­ma­ceuti­cals, medical devices, foods for special medical purposes and dietary supple­ments are also explained. The Medication Manual explains the therapy concept and provides nume­rous sug­ges­tions for basic therapy and sympto­matic additional treat­ment of the chronic phase as well as for the treat­ment of acute phases. It also presents treat­ment in special situ­ations such as ana­phylaxis / ana­phylactic shock, infectious diseases, vacci­nations, pollen allergies, pregnancy and breast­feeding, as well as pre­medi­cation and other pre­cautions regarding anesthe­sia, surgery and dental treat­ment. There is also a list of incompa­tible active substances and instruc­tions on how to assess the toler­ance of pharma­ceuti­cal products. This is comple­mented by many other tips and tricks.

[PDF VORSCHAU]SIGHI_Medication_Manual_PREVIEW.pdf
(1 MB, version 2019-01-03)
[PDF][password protected]SIGHI_Medication_Manual.pdf
(3 MB, version 2019-01-03)

Internal document for members only. No retail sale.


Here we can only briefly explain the most important classes of active ingredients:

Antihistamines

Antihistamines (histamine receptor antagonists) can be used to block the histamine receptors on the surface of cells. H1-receptors are blocked with H1-antihistamines to prevent most symptoms. Additionally, H2-receptors are blocked with an H2-antihistamine in case of excess gastric acid or other gastric / intestinal symptoms.

Diamine oxidase (DAO)

Diamine oxidase capsules can be taken before meals to decompose intestinal histamine before uptake. It has an effect only against histamine in foods, but not against histamine liberators and not against endogenous histamine released by mast cells.

Mast cell stabilisators

Some active substances are able to stabilise mast cells. Some act only locally, some are systemic.

Food supplements

Some food supplements like ascorbic acid, zinc or magnesium may have a slight positive effect. Ascorbic acid lowers the histamine level, but is also a slight DAO-inhibitor. It seems that ascorbic acid has a positive effect in mast cell diseases but may have negative effects in those concerned with histamine intolerance.

Incompatible medicaments

Histamine liberators

Many agents in medicaments (active substances as well as additives) have the negative effect that they cause mast cell degranulation which leads to release of histamine and other mast cell mediators. They have to be avoided where ever possible according to the agreement with your physician.

DAO-Inhibitors

Many agents in medicaments have the negative effect that they are diamine oxidase inhibitors or inhibitors of other histamine degrading enzymes. They have to be avoided where ever possible according to the agreement with your physician.

List of incompatible active substances in medicaments

This list needs to be completed. Please let us know your experiences with other substances.

Active substanceExamples of products ®CategoriesHistamine effectsReferences
AcemetacinAntirheumaticDAO inhibitor[Sattler 1985, Fritzsche 2009]
Acetyl­cysteineFluimucil, Helvetussin, Muco-Mepha, NeoCitran, SolmucolMucolytic, antidoteDAO inhibitor[Jarisch 2004, Maintz et al. 2006]
Acetylsalicylic acid, ASSAspirinAnalgesicHistamine liberator[Jarisch 2004, Maintz et al. 2006]
AcriflavinAntisepticDAO inhibitor[Fritzsche 2009]
AlcuroniumMuscle relaxantDAO inhibitor[Sattler 1985, Maintz et al. 2006, Forth 2008]
AlprenololBeta blockerDAO inhibitor[Maintz et al. 2006]
AmbroxolAmbrovene, Ambroxol, Broxol, Mucosolvan, MucospasExpectorantDAO inhibitor[Jarisch 2004, Maintz et al. 2006]
AmilorideDiuretic?[Maintz et al. 2006]
AminocyclineDAO inhibitor[Sattler 1985]
AminophyllinEuphyllin, Mundiphyllin, MyocardonAntiasthmaticDAO inhibitor[Sattler 1985, Jarisch 2004, Maintz et al. 2006]
AmiphenazoleDAO inhibitor[Sattler 1985]
AmitriptylineSaroten, Tryptizol, LimbritolTricyclic antidepressantDAO inhibitor[Jarisch 2004, Maintz et al. 2006]
AmodiaquinsAntimalarialsHNMT-Blocker[Horton et al. 2005, Aschenbach 2002]
AmphetamineHistamine liberator[Uni Bochum]
Ampho­teri­cin BAntibioticHistamine liberator[Livingstone 2013, Büttiker]
AtracuriumMuscle relaxantHistamine liberator[Sido et al. 2014, Dewachter et al. 2014]
AtropineHistamine liberator[Büttiker]
BarbituratesHypnotics, sedatives, anaestheticsHistamine liberator[Steneberg 2007]
Bile acids, bile saltsHistamine liberator[Büttiker]
BupropionNDRIHistamine liberator[Afrin et al. 2015]
CarbamazepineAnticonvulsantHistamine liberator[Afrin et al. 2015]
CarbocromeneDAO inhibitor[Sattler 1985]
CefotiamAntibioticDAO inhibitor[Maintz et al. 2006]
CefuroximeAntibioticHistamine liberator[Sido et al. 2014, Maintz et al. 2006]
ChloroquineChlorochin, Nivaquine, ResochinAntimalarials, antirheumaticDAO inhibitor, HNMT-Blocker[Sattler 1985, Jarisch 2004, Donatelli et al. 1994, Maintz et al. 2006]
Chlortetra­cyclinsAntibioticHistamine liberator[Büttiker]
CimetidineH2 antihistamineDAO inhibitor[Prof. Ralf Bauer Uni Bonn; found in: Jarisch 2004 S.12, Maintz et al. 2006, Fritzsche 2009]
CiprofloxacinAntibioticHistamine liberator[Livingstone 2013, SIGHI: 1 Fallbericht]
Clavulanic acidAugmentinAntibioticDAO inhibitor[Sattler 1985, Jarisch 2004, Maintz et al. 2006]
CodeineOpiate, analgesic, cough medicineHistamine liberator[Afrin et al. 2015, , Steneberg 2007]
Colistin mesilateDAO inhibitor[Sattler 1985]
CurareArrow poison alkaloids, anaesthetic[Büttiker]
CyclophosphamideCytostatic ?[Maintz et al. 2006]
D-CycloserineSeromycinAntibioticDAO inhibitor (Vitamin B6-Antagonist)[Sattler 1985, Steneberg 2007]
Decamethoni­umHistamine liberator[Büttiker]
DextranesSephadexBlood plasma substitute, antithromboticHistamine liberator[Giertz und Hahn 1966, Büttiker]
DiazepamValiumTranquilizerDAO inhibitor[Fritzsche 2009]
DiclofenacVoltarenAntirheumaticHistamine liberator[Jarisch 2004]
DihydralazineNepresolAntihypertensive, vasodilatorDAO inhibitor[Wantke et al. 1989, Sattler 1985, Maintz et al. 2006, Fritzsche 2009]
Diphen­hydramineNardyl, BenoctenSedative, antihistamineHNMT-Blocker[Horton et al. 2005, Farag et al. 2008]
Dipyrone: see Metamizol
DobutamineAntihypotonic?[Maintz et al. 2006]
FenpiveriniumDAO inhibitor[Sattler 1985]
FlurbiprofenHistamine liberator[Jarisch 2004]
FramycetinAntibioticDAO inhibitor[Sattler 1985, Fritzsche 2009]
FurosemideLasixDiureticDAO inhibitor[Fritzsche 2009]
Gadolinium chelatesX-ray contrast mediaHistamine liberator[Sido et al. 2014]
GallaminesHistamine liberator[Büttiker]
GelatinePlasma substituteHistamine liberator[Sido et al. 2014]
Glyceroltri­nitrate, glyceryl­trinitrate, nitroglycerin, Propan­triol­trinitratVasodilatorHistamine liberator[Pedersen et al. 2015]
HaloperidolHaldolNeurolepticDAO inhibitor[Fritzsche 2009]
HeroinHistamine liberator[Nesterenko 2010]
HydralazineHistamine liberator[Uni Bochum]
Hydroxyethyl starchPlasma substituteHistamine liberator[Sido et al. 2014]
IndomethacinHistamine liberator[Jarisch 2004]
IsoniazideRimifon, RifaterTuberculostaticDAO inhibitor (Vitamin B6-Antagonist)[Jarisch 2004, Maintz et al. 2006]
KetoprofenHistamine liberator[Jarisch 2004]
Latex glovesHistamine liberator[Sido et al. 2014]
LevofloxacinAntibioticHistamine liberator[Sido et al. 2014]
Meclofenamic acidHistamine liberator[Jarisch 2004]
Mefenamic acid[Jarisch 2004]
Meperidine: see pethidineOpioid
Metamizole, dipyronesNovalgin, MinalginAnalgesic, antipyreticDAO inhibitor[Jarisch 2004, Maintz et al. 2006]
MethohexitalInjection narcoticHistamine liberator[Sido et al. 2014]
MetoclopramideMigpriv, Paspertin, PrimperanAntiemetic, gastroenterologic, dopamine antagonistDAO inhibitor[Sattler 1985, Jarisch 2004, Maintz et al. 2006]
MetoprineHNMT-Blocker[Horton et al. 2005, Jochem]
MivacuriumMuscle relaxantHistamine liberator[Sido et al. 2014, Dewachter et al. 2014]
MorphineAnalgesic, opioidHistamine liberator[Afrin et al. 2015, Maintz et al. 2006, Steneberg 2007, Forth 2008]
NaproxenHistamine liberator[Jarisch 2004]
NefopamAnalgesicHistamine liberator[Dewachter et al. 2014]
NeomycinAntibioticDAO inhibitor[Mathelier-Fusade 2006]
Nitroglycerin, glycerol trinitrate, glyceryl trinitrate, propane triol trinitrateVasodilatorHistamine liberator[Pedersen et al. 2015]
Nonsteroidal anti-inflammatory drugs (NSAID)AnalgesicHistamine liberator[Sido et al. 2014]
NoscapineAnalgesicHistamine liberator[Büttiker]
Novamine sulfone(=Metamizol) Novalgin, MinalginAnalgesic, antipyreticDAO inhibitor[Jarisch 2004]
NSAP, NSAR, NSAIDVerträglichkeit individuell!NSAR, NSAID(Histamine liberator)[Afrin et al. 2015]
Opiates, Opioids(Heroin, Morphium)AalgesicHistamine liberator[Sido et al. 2014, Wirz and Molderings 2017]
OrciprenalineDAO inhibitor[Sattler 1985]
PancuroniumMuscle relaxantDAO inhibitor[Sattler 1985, Maintz et al. 2006, Fritzsche 2009]
PapaverineHistamine liberator[Büttiker]
PentamidineAntibioticDAO inhibitor[Sattler 1985, Maintz et al. 2006]
Pethidine, MeperidineAnalgesic, opioidHistamine liberator[Sido et al. 2014, Wirz and Molderings 2017, Afrin et al. 2015, Maintz et al. 2006, Forth 2008]
PhenobarbitalInjection narcoticHistamine liberator[Sido et al. 2014]
PilocarpineHistamine liberator[Büttiker]
PirenzepineDAO inhibitor[Sattler 1985]
Polymyxin BAntibioticHistamine liberator[Büttiker]
Polyvinyl­pyrroli­done (E1201)Povidone, PVP, PeristonBlood plasma substitute, antithrombotic, excipient in tablets and capsulesHistamine liberator[Giertz und Hahn 1966, Novartis 2008]
PrilocaineLocal anaestheticDAO inhibitor[Maintz et al. 2006, Nesterenko 2010]
ProcaineLocal anaestheticHistamine liberator[Sido et al. 2014]
PromethazineAtosil, Closin, Proneurin, ProthazinSedative, antihistamine, antipsychoticDAO inhibitor[Irion 2009]
PropafenoneRytmonormAntiarrhythmic DAO inhibitor[Jarisch 2004, Maintz et al. 2006]
PropanidideAnaestheticDAO inhibitor[Nesterenko 2010]
ProtamineHeparin antagonizationHistamine liberator[Sido et al. 2014; Horrow 1985]
PyrazolonesAnalgesicHistamine liberator[Büttiker]
QuinidineCardiacDAO inhibitor[Fritzsche 2009]
QuinineHistamine liberator[Büttiker]
ReserpineHistamine liberator[Büttiker]
RifampicinAntibioticHistamine liberator[Livingstone 2013]
RifaximinAntibioticHistamine liberator[1 Einzelfallbericht SIGHI]
ScopolamineHistamine liberator[Büttiker]
SSRIs, selective serotonin reuptake inhibitorsAntidepressantUnver­träg­lich[Afrin et al. 2015]
StilbamidineHistamine liberator[Büttiker]
Suxa­metho­niumMuscle relaxantHistamine liberator[Forth 2008Sido et al. 2014]
TacrinAcetylcholinesterase inhibitor, Alzheimer's drugHNMT-Blocker[Cumming and Vincent 1992, Taraschenko et al. 2005]
TeicoplaninAntibioticHistamine liberator[Livingstone 2013]
TetracaineLocal anaestheticHistamine liberator[Sido et al. 2014]
TetroxoprimDAO inhibitor[Sattler 1985]
Thiamine (vitamin B1)(In parenteral administration. Compatible with food.)Histaminliberator, DAO inhibitor[Büttiker, Sattler 1985]
ThiopentalSedativeHistamin­libe­ra­tor / DAO inhibitor ?[Sido et al. 2014, Maintz et al. 2006]
TolazolineHistamine liberator[Uni Bochum]
TopiramateMigraine, anti-epilepticHistamine liberator[Afrin et al. 2015]
tricyclic antidepressantsUnver­träg­lich[Afrin et al. 2015]
Tubocurarins, D-TubocurarinMuscle relaxantHistamine liberator[Sattler 1985, Maintz et al. 2006, Forth 2008, Steneberg 2007]
TyramineHistamine liberator[Uni Bochum]
VancomycineAntibioticHistamine liberator[Sido et al. 2014, Livingstone 2013]
VerapamilFlamon, Isoptin, TarkaCoronary vaso­dilatant, anti­hyper­tensive, anti­arrhythmic, calcium antagonistDAO inhibitor[Jarisch 2004, Maintz et al. 2006]
X-ray contrast mediaAll of them!X-ray contrast mediaHistamine liberator[Jarisch 2004]
ß-Adrenoceptor blockersHistamine liberator[Sido et al. 2014]

Compatible alternatives

For compatible alternatives please have a look at the SIGHI Medication Manual.


Guided tour: go to
therapy > way of life



References and bibliography

The "back"-button of your browser takes you back to the previous position.

ABack to the previous position
Afrin et al. 2015Afrin LB, Pöhlau D, Raithel M, Haenisch B, Dumoulin FL, Homann J, Mauer UM, Harzer S, Molderings GJ.: "Mast Cell Activation Disease: An Under­appreciated Cause of Neurologic and Psychiatric Symptoms and Diseases." Brain Behav Immun. 2015 Jul 7. pii: S0889-1591(15)00236-6. doi: 10.1016/j.bbi.2015.07.002.
https://pubmed.ncbi.nlm.nih.gov/26162709
("We describe MCAD's pathogenesis, presentation (focusing on [central and/or peripheral neurologic and/or psychiatric symptoms] (NPS)), and therapy, especially vis-à-vis neuro­psychotropes. Since MCAD patients often present NPS, neurologists and psychiatrists have the opportunity, in recognizing the diagnostic possibility of MCAD, to short-circuit the often decades-long delay in establishing the correct diagnosis required to identify optimal therapy.")
Aschenbach et al. 2002Aschenbach JR, Ahrens F, Garz B, Gäbel G.: "Paracellular tightness and catabolism restrict histamine permeation in the proximal colon of pigs". Pflugers Arch. 2002 Oct;445(1):115-22. Epub 2002 Jul 16. https://www.ncbi.nlm.nih.gov/pubmed/12397395
BBack to the previous position
Bielenberg 2005Bielenberg, Jens: "Korrelate einer schadstoffinduzierten Veränderung des Histaminstoffwechsels? Die Allergie-Hypothese". Österreichische Apotheker-Zeitung ÖAZ Aktuell (Ausgabe 15/2005), Hauptartikel 15/2005. Anschrift des Autors: Apotheker Jens Bielenberg, Raphael-Apotheke, D-25364 Westerhorn, Bahnhofstr. 53
Der Artikel ist inzwischen online nicht mehr auffindbar. Ein sehr ähnlicher Text desselben Autors ist hier abrufbar:
Bielenberg, Jens: "Die Allergie-Hypothese – Fakt oder Fiktion? Allergien - Korrelate einer schadstoffinduzierten Veränderung des Histaminstoffwechsels?". Ärztezeitschrift für Naturheilverfahren 46, 11 (2005).https://www.yumpu.com/de/document/view/6248824/die-allergie-hypothese-fakt-oder-fiktion-zentralverband-der-
(Interessanter Artikel über mögliche Ursachen von Allergien, Störfaktoren im Histaminstoffwechsel, Abbaumechanismen von Histamin, Ascorbate (Vitamin C), Umweltschadstoffe, Schilddrüsenerkrankungen)
BüttikerDr. med. U. Büttiker, Konsiliararzt Universitätsklinik Bern: "Histaminliberatoren", http://www.hautarzt-bubenberg.ch/sites/hautarzt-bubenberg.ch/files/pdf/Histaminliberatoren.pdf, abgerufen am 16.07.2011.
CBack to the previous position
Cumming and Vincent 1992Cumming P, Vincent SR.: "Inhibition of histamine-N-methyltransferase (HNMT) by fragments of 9-amino-1,2,3,4-tetrahydro­acridine (tacrine) and by beta-carbolines." Biochem Pharmacol. 1992 Sep 1;44(5):989-92.
https://pubmed.ncbi.nlm.nih.gov/1530666
("Histamine-N-methyltransferase (HNMT), the major enzyme for the metabolism of histamine in rat brain, is potently inhibited by 9-amino-1,2,3,4-tetrahydroacridine (tacrine).")
DBack to the previous position
Donatelli et al. 1994Donatelli, P., Marchi, G., Giuliani, L., Gustafsson, L.L., Pacifici, G.M.: "Stereoselective inhibition by chloroquine of histamine N-methyltransferase in the human liver and brain.", Eur. J. Clin. Pharmacol. (1994). www.wikigenes.org/e/ref/e/7875186.html
FBack to the previous position
Farag et al. 2008Farag NA, Mohamed SR, Soliman GA.: "Design, synthesis, and docking studies of novel benzopyrone derivatives as H(1)-antihistaminic agents." Bioorg Med Chem. 2008 Oct 1;16(19):9009-17. doi: 10.1016/j.bmc.2008.08.039. Epub 2008 Aug 26.
https://pubmed.ncbi.nlm.nih.gov/18789706
("histamine N-methyltranseferase (HNMT) active site in complex with its bound inhibitor (diphenhydramine)")
Forth 2008Forth, Wolfgang; Hofmann, Franz; Förstermann, Ulrich: "Allgemeine und spezielle Pharmakologie und Toxikologie", 9. Auflage, Elsevier,Urban&Fischer Verlag, 2008.
Fritzsche 2009Fritzsche, Doris: "GU Kompass Nahrungsmittel Intoleranzen, Laktose, Fruktose, Histamin", Gräfe und Unzer Verlag, 1. Auflage 2009. ISBN 978-3-8338-1368-9.
GBack to the previous position
Giertz und Hahn 1966H. Giertz und F: Hahn: "Makromolekulare Histaminliberatoren", In: Mauricio Rocha e Silva (Hrsg.): Histamine and Anti-Histaminics Part 1. Handbuch der experimentellen Pharmakologie Band XVIII/1. Berlin, Springer-Verlag 1966, hier Seite 481–568
Gilfillan and Beaven 2011Gilfillan AM, Beaven MA.: "Regulation of mast cell responses in health and disease." Crit Rev Immunol. 2011;31(6):475-529.
https://pubmed.ncbi.nlm.nih.gov/22321108
(Das Antibiotikum Novalgin ist ein Histaminliberator.)
HBack to the previous position
Horton et al. 2005Horton JR, Sawada K, Nishibori M, Cheng X.: "Structural basis for inhibition of histamine N-methyltransferase by diverse drugs". J Mol Biol. 2005 Oct 21;353(2):334-44.
https://pubmed.ncbi.nlm.nih.gov/16168438
(Medikamentenwirkstoffe als HNMT-Blocker: Folgende Stoffe, von denen bekannt ist, dass sie starke HNMT-Inhibitoren sind, wurden darauf hin untersucht, auf welche Weise sie den Histaminabbau blockieren: Diphenhydramine (ein H1-Antihistaminikum!), Amodiaquine, Metoprine, Tacrine. Alle blockieren die Histamin-Bindungsstelle des Enzyms, so dass kein Histamin mehr zum aktiven Zentrum der HNMT gelangen kann.)
IBack to the previous position
Irion 2009Dr. Roland Irion: Internetseite "Biogene Amine. Auslöser von pseudoallergischen Reaktionen".
http://www.alles-zur-allergologie.de/Allergologie/Artikel/3526/Allergen,Allergie/Biogene%20Amine/, abgerufen am 30.04.2013.
JBack to the previous position
Jarisch 2004Jarisch, Reinhart: "Histamin-Intoleranz, Histamin und Seekrankheit", Thieme Verlag, 2004, ISBN 3-13-105382-8.
Jarisch 2005Jarisch, Reinhart: "Histamin-Intoleranz: Ein oft übersehenes Problem". Arzt & Praxis VerlagsGmbH, Wien, Sonderdruck Oktober 2005, Heft Nr. 908, S. 380-382, 59. Jahrgang.
http://www.reizmageninfo.de/ArztPraxis_2005_Jarisch.pdf, abgerufen am 08.11.2009 (inzwischen nicht mehr abrufbar).
Jochem 2004Jochem J.: "Cardiac and regional haemodynamic effects of histamine N-methyltransferase inhibitor metoprine in haemorrhage-shocked rats." Inflamm Res. 2004 Jul;53(7):316-23. Epub 2004 Jun 25.
https://pubmed.ncbi.nlm.nih.gov/15241567,
Metoprin = HNMT-Hemmer
KBack to the previous position
Komericki et al. 2010Peter Komericki, Georg Klein, Norbert Reider, Thomas Hawranek, Tanja Strimitzer, Roland Lang,Bettina Kranzelbinder, Werner Aberer: "Histamine intolerance: lack of reproducibility of single symptoms by oral provocation with histamine: A randomised, double-blind, placebo-controlled cross-over study", Wien Klin Wochenschr (2010). DOI 10.1007/s00508-010-1506-y.
https://pubmed.ncbi.nlm.nih.gov/21165702,
http://pubget.com/paper/21165702, abgerufen am 11.12.2011.
Erfolgreicher Wirksamkeitsnachweis von Diaminoxidasepräparaten (DAOSIN). Zudem wurde gezeigt, dass das Auftreten einzelner Symptome nicht reproduzierbar ist. Es ist sinnlos, eine Korrelation zwischen der Histaminbelastung und einem bestimmten Symptom zu suchen. Man sollte in Studien immer die gesamte Palette der histaminvermittelten Symptomatik als Ganzes erfassen.
LBack to the previous position
Livingstone 2013Dr. med. Elisabeth Livingstone, PD Dr. med. Uwe Hillen, PD Dr. med. Andreas Körber: "Unerwünschte Arzneimittelreaktionen" PowerPoint Präsentation Universitätsklinikum Essen.
www.uk-essen.de/fileadmin/user_upload/hautklinik/fuer_studenten/arzneireaktionen_livingstone_23_05_2013.pdf (nicht mehr abrufbar)
MBack to the previous position
Mathelier-Fusade 2006Mathelier-Fusade P.: "Drug-induced urticarias" Clin Rev Allergy Immunol. 2006 Feb;30(1):19-23.
https://pubmed.ncbi.nlm.nih.gov/16461991
Gelesen in Gilfillan and Beaven 2011.
(Das Antibiotikum Novalgin ist ein DAO-Inhibitor.)
Medivere GmbHganzimmun.ch: "Ernährungsempfehlungen bei Histamin-Intoleranz", Medivere GmbH.
http://www.histaminose.de/07_pdf/histamin.pdf, abgerufen am 06.12.2009 (inzwischen nicht mehr abrufbar).
www.ganzimmun.ch/seiten/download_file.php?download_id=1855, abgerufen am 1.9.2014.
NBack to the previous position
Nesterenko 2010Nesterenko, Sigi: "Histaminintoleranz - die unentdeckte Krankheit", Rainer Bloch Verlag, 2010, ISBN-10: 3981095189, ISBN-13: 978-3981095180.
Novartis 2008Novartis: "FACHINFORMATION Program® 40, Suspension zur Injektion für Katzen", Juli 2008.
http://www.ah.novartis.de/platform/content/element/1612/ProgramInj40-Katze.pdf, abgerufen am 12.2.2013.
("Nicht bei Hunden anwenden. Der Hilfsstoff Polyvinylpyrrolidon (Povidon) ist für Hunde eine starke Histamin freisetzende Substanz. Beim Hund können deshalb, im Gegensatz zuKatzen, schwere Reaktionen auftreten.") Anm. d. Red.: Hunde erkranken besonders häufig an Mastozytomen oder Mastzellsarkomen. Ein Indiz, dass Mastozytosepatienten auf Povidon vielleicht ähnlich empfindlich reagieren könnten wie Hunde?
OBack to the previous position
O'Sullivan et al. 2006O'Sullivan J, O'Sullivan MI, Tipton KE, Davey G.: "Inhibition of amine oxidases by the histamine-1 receptor antagonist hydroxyzine". J Neural Transm Suppl. 2006;(71):105-12.
https://pubmed.ncbi.nlm.nih.gov/17447421
(Hydroxyzine (ein H1-Antihistaminikum!) blockiert die DAO.)
PBack to the previous position
Pedersen et al. 2015Pedersen SH, Ramachandran R, Amrutkar DV, Petersen S, Olesen J, Jansen-Olesen: "Mechanisms of glyceryl trinitrate provoked mast cell degranulation." Cephalalgia. 2015 Feb 27. pii: 0333102415574846.
https://pubmed.ncbi.nlm.nih.gov/25724914
(Intravenös verabreichtes Glyceroltrinitrat (Nitroglyzerin) führt einige Stunden nach der Injektion zu starker Mastzelldegranulation. Mechanismus noch unbekannt.)
SBack to the previous position
Sattler et al. 1987Sattler J, Hesterberg R, Schmidt U, Crombach M, Lorenz W.: "Inhibition of intestinal diamine oxidase by detergents: a problem for drug formulations with water insoluble agents applied by the intravenous route?" Agents Actions. 1987 Apr;20(3-4):270-3.
https://pubmed.ncbi.nlm.nih.gov/3111194
(Intravenös verabreichte Medikamente enthalten oft Detergentien/Tenside als Hilfsstoffe. Mehrere dieser Detergentien erwiesen sich als DAO-Hemmer und könnten für Unverträglichkeitsreaktionen auf Medikamente verantwortlich sein.)
Sattler et al. 1985Sattler J, Hesterberg R, Lorenz W, Schmidt U, Crombach M, Stahlknecht CD.: "Inhibition of human and canine diamine oxidase by drugs used in an intensive care unit: relevance for clinical side effects?" Agents Actions. 1985 Apr;16(3-4):91-4.
https://pubmed.ncbi.nlm.nih.gov/3925736
(Liste unverträglicher Medikamente (DAO-Hemmer))
Steneberg 2007Steneberg, Andreas: "Biogene Amine – Ernährung bei Histamin-Intoleranz", Umwelt & Gesundheit 2/2007.
http://www.iug-umwelt-gesundheit.de/pdf/072_47_56_SP_HIT_neu.pdf, abgerufen am 06.11.2009.
TBack to the previous position
Taraschenko et al. 2005Taraschenko OD, Barnes WG, Herrick-Davis K, Yokoyama Y, Boyd DL, Hough LB.: "Actions of tacrine and galanthamine on histamine-N-methyltransferase." Methods Find Exp Clin Pharmacol. 2005 Apr;27(3):161-5.
https://pubmed.ncbi.nlm.nih.gov/15834447
("Tacrine (0.01-10 microM) inhibited both human and rat HNMT activity in a concentration-dependent manner, but was less potent on both human embryonic kidney and recombinant human brain HNMT than on rat kidney HNMT [...]. Tacrine, but not galanthamine, may achieve brain levels sufficient to influence histamine metabolism in some patients treated for Alzheimer's disease.")
UBack to the previous position
Uni BochumKlinik für Dermatologie, Venerologie und Allergologie, Ruhr-Universität Bochum – St. Josef-Hospital: "Patienteninformation Mastozytose", undatiert.
http://www.derma.de/bochum/tl_files/dermatologie/dermatologie-pdf/Informationsblaetter/Merkblaetter_Mastozytose.pdf, abgerufen am 23.12.2014.
YBack to the previous positione
Yokoyama 2007Yokoyama A, Mori S, Takahashi HK, Kanke T, Wake H, Nishibori M: "Effect of amodiaquine, a histamine N-methyltransferase inhibitor, on, Propionibacterium acnes and lipopolysaccharide-induced hepatitis in mice", Eur J Pharmacol. 2007 Mar 8;558(1-3):179-84. Epub 2006 Nov 22.
https://pubmed.ncbi.nlm.nih.gov/17222819, abgerufen am 13.06.2010.






^   Updated: 18.03.2023  |  © Copyright by SIGHI
   Bank details  |  Privacy  |  Important notes